The heterogeneous expression of MAGE-3 protein: difference between primary lesions and metastatic lymph nodes in gastric carcinoma.

N. Sadanaga, H. Nagashima, K. Tahara, Y. Yoshikawa, Masaki Mori

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We evaluated the expression of MAGE-3 protein in gastric carcinoma by immunohistochemistry, and compared the frequency between primary lesions and metastatic lymph nodes. Primary lesions and metastatic lymph nodes of 38 cases of gastric carcinoma were analyzed using anti-MAGE-3 monoclonal antibody. Expression of MAGE-3 protein was detected in 17 (45%) primary lesions and 12 (32%) metastatic lymph nodes of 38 cases. In 70% of positive cases of primary lesions, the percentage of stained cells with MAGE-3 decreased in metastatic lymph nodes. The heterogeneous expression of MAGE-3 should be considered when we perform antigen specific immunotherapy for patients with gastric carcinoma.

Original languageEnglish
Pages (from-to)975-977
Number of pages3
JournalOncology reports
Volume6
Issue number5
Publication statusPublished - Jan 1 1999

Fingerprint

Stomach
Lymph Nodes
Carcinoma
Proteins
Immunotherapy
Immunohistochemistry
Monoclonal Antibodies
Antigens

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The heterogeneous expression of MAGE-3 protein : difference between primary lesions and metastatic lymph nodes in gastric carcinoma. / Sadanaga, N.; Nagashima, H.; Tahara, K.; Yoshikawa, Y.; Mori, Masaki.

In: Oncology reports, Vol. 6, No. 5, 01.01.1999, p. 975-977.

Research output: Contribution to journalArticle

@article{601d51c1491f4508a9f129f6a00fdd04,
title = "The heterogeneous expression of MAGE-3 protein: difference between primary lesions and metastatic lymph nodes in gastric carcinoma.",
abstract = "We evaluated the expression of MAGE-3 protein in gastric carcinoma by immunohistochemistry, and compared the frequency between primary lesions and metastatic lymph nodes. Primary lesions and metastatic lymph nodes of 38 cases of gastric carcinoma were analyzed using anti-MAGE-3 monoclonal antibody. Expression of MAGE-3 protein was detected in 17 (45{\%}) primary lesions and 12 (32{\%}) metastatic lymph nodes of 38 cases. In 70{\%} of positive cases of primary lesions, the percentage of stained cells with MAGE-3 decreased in metastatic lymph nodes. The heterogeneous expression of MAGE-3 should be considered when we perform antigen specific immunotherapy for patients with gastric carcinoma.",
author = "N. Sadanaga and H. Nagashima and K. Tahara and Y. Yoshikawa and Masaki Mori",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "975--977",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - The heterogeneous expression of MAGE-3 protein

T2 - difference between primary lesions and metastatic lymph nodes in gastric carcinoma.

AU - Sadanaga, N.

AU - Nagashima, H.

AU - Tahara, K.

AU - Yoshikawa, Y.

AU - Mori, Masaki

PY - 1999/1/1

Y1 - 1999/1/1

N2 - We evaluated the expression of MAGE-3 protein in gastric carcinoma by immunohistochemistry, and compared the frequency between primary lesions and metastatic lymph nodes. Primary lesions and metastatic lymph nodes of 38 cases of gastric carcinoma were analyzed using anti-MAGE-3 monoclonal antibody. Expression of MAGE-3 protein was detected in 17 (45%) primary lesions and 12 (32%) metastatic lymph nodes of 38 cases. In 70% of positive cases of primary lesions, the percentage of stained cells with MAGE-3 decreased in metastatic lymph nodes. The heterogeneous expression of MAGE-3 should be considered when we perform antigen specific immunotherapy for patients with gastric carcinoma.

AB - We evaluated the expression of MAGE-3 protein in gastric carcinoma by immunohistochemistry, and compared the frequency between primary lesions and metastatic lymph nodes. Primary lesions and metastatic lymph nodes of 38 cases of gastric carcinoma were analyzed using anti-MAGE-3 monoclonal antibody. Expression of MAGE-3 protein was detected in 17 (45%) primary lesions and 12 (32%) metastatic lymph nodes of 38 cases. In 70% of positive cases of primary lesions, the percentage of stained cells with MAGE-3 decreased in metastatic lymph nodes. The heterogeneous expression of MAGE-3 should be considered when we perform antigen specific immunotherapy for patients with gastric carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0033190659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033190659&partnerID=8YFLogxK

M3 - Article

C2 - 10425289

AN - SCOPUS:0033190659

VL - 6

SP - 975

EP - 977

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -